What is short bowel syndrome?

Short bowel syndrome (SBS) is a malabsorptive condition resulting from surgical resection of a significant portion of the small intestine (or congenital short bowel), leaving insufficient absorptive surface area to maintain nutrition and hydration through oral/enteral intake alone. Patients often require intravenous parenteral nutrition and/or fluids, which carries risks of liver disease, catheter infections, and reduced quality of life.

How does teduglutide differ from GLP-1 agonists like semaglutide?

They are entirely different drugs. Teduglutide is a GLP-2 analog that promotes intestinal mucosal growth for SBS. GLP-1 agonists like semaglutide target the GLP-1 receptor and are used for diabetes and obesity. GLP-1 and GLP-2 are distinct hormones with different receptors and biological effects, though both are derived from proglucagon.

Does teduglutide increase cancer risk?

Teduglutide stimulates intestinal cell proliferation, raising a theoretical concern about accelerating growth of pre-existing neoplasms. The FDA requires colonoscopy within 6 months before starting treatment and surveillance every 5 years during treatment. It is contraindicated in patients with active GI malignancy. No causal link to cancer has been established in clinical trials, but long-term surveillance data continues to accumulate.

What is the recommended dose range for Teduglutide?

The research dose range is 0.05 mg/kg once daily, administered via Subcutaneous injection, Once daily.

peptide dosing

Teduglutide Dosing & Reconstitution Guide

Complete dosing reference for Teduglutide (Gastrointestinal / GLP-2 Analog). Covers reconstitution, dose range, titration schedule, pharmacokinetics, and storage protocols for research use.

Dosing Protocol

Route: Subcutaneous injection Frequency: Once daily Dose Range: 0.05 mg/kg once daily Timing: Same time each day; rotate injection sites

Storage

Lyophilized: Refrigerate at 2-8 °C (36-46 °F) Reconstituted: Use within 3 hours of reconstitution; do not refrigerate after reconstitution

Injection Sites

Abdomen, Thigh, Upper arm

Safety & Contraindications

Safety: Common (>=10%): abdominal pain, nausea, injection site reactions, headache, abdominal distension, upper respiratory tract infection GI-related: intestinal obstruction, pancreatitis, biliary and pancreatic duct stenosis reported Potential for accelerated neoplastic growth: FDA requires colonoscopy within 6 months before starting and at least every 5 years during treatment

Contraindications: Active GI malignancy or history of GI malignancy within the past 5 years; Known hypersensitivity to teduglutide; Patients must have colonoscopy with removal of polyps within 6 months before starting treatment

Peptide Tools

Reconstitution CalculatorCalculate concentration and syringe units for any peptide vial with visual syringe guide.

Dosage & Cycle PlannerPlan a multi-week peptide cycle. Calculate total supply needed and vial counts.

Bacteriostatic Water CalculatorCalculate how many vials of bacteriostatic water you need for your peptide stack.

Cost-Per-Milligram CalculatorCompare vendors side-by-side. Find the best value per milligram and per dose.

Frequently Asked Questions

Related Resources

Browse All Research Peptides

Explore More

Teduglutide Dosing Guide Peptides for Short Bowel Syndrome Peptides for Parenteral Nutrition Reduction

Research Use Only. The information on this page is compiled from published research literature and is provided for educational purposes only. It does not constitute medical advice. All compounds referenced are intended for in vitro research use by qualified laboratories and institutions.